Published in Am J Cancer Res on May 01, 2016
Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51
Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21
The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med (2001) 11.94
Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov (2010) 4.47
Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med (2011) 2.77
Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem (2011) 2.70
ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia (2009) 2.43
ABCG2: a perspective. Adv Drug Deliv Rev (2008) 1.97
Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol (2010) 1.82
Phage display: concept, innovations, applications and future. Biotechnol Adv (2010) 1.77
The cell cycle and cancer. J Pathol (2011) 1.67
Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res (2004) 1.54
Chemoresistance in solid tumours. Ann Oncol (2006) 1.39
Phage display in molecular imaging and diagnosis of cancer. Chem Rev (2010) 1.34
ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood (2006) 1.27
Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol (2013) 1.25
The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo. Biochem Pharmacol (1992) 1.18
BCRP gene expression is associated with a poor response to remission induction therapy in childhood acute myeloid leukemia. Leukemia (2002) 1.17
Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J (2011) 1.17
Role of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update. AAPS J (2014) 1.17
Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer. Lung Cancer (2008) 1.14
ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology (2007) 1.12
Advances in treatment of lung cancer with targeted therapy. Arch Pathol Lab Med (2012) 1.11
Transferrin receptor-mediated endocytosis: a useful target for cancer therapy. J Membr Biol (2014) 1.04
Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs (2012) 1.04
ABCG2 is related with the grade of glioma and resistance to mitoxantone, a chemotherapeutic drug for glioma. J Cancer Res Clin Oncol (2009) 1.01
Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer (2010) 0.90
Development trends for generation of single-chain antibody fragments. Immunopharmacol Immunotoxicol (2014) 0.81
Production and radioimmunoimaging of novel fully human phage display recombinant antibodies and growth inhibition of lung adenocarcinoma cell line overexpressing Prx I. Cancer Biol Ther (2009) 0.81
The Role of Multidrug Resistance Efflux Pumps in Cancer: Revisiting a JNCI Publication Exploring Expression of the MDR1 (P-glycoprotein) Gene. J Natl Cancer Inst (2015) 0.81
ABCG2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. Am J Hematol (2015) 0.78
Cloning and expression of an anti-LDL(-) single-chain variable fragment, and its inhibitory effect on experimental atherosclerosis. MAbs (2013) 0.77
Cell death in cancer therapy of lung adenocarcinoma. Int J Dev Biol (2015) 0.77